GlassScriptPhysician profile
Michael R Wisser
NPI 1386676617
$4,024.00
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $444 · 2021: $389 · 2022: $1,071 · 2023: $373 · 2024: $39.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $610.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $451.51 | 2019-2023 | Breztri |
| Abbvie INC. | $447.30 | 2021-2023 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.56 | 2019-2023 | Jardiance |
| Pfizer INC. | $286.77 | 2019-2023 | |
| Lilly USA, LLC | $227.91 | 2019-2023 | Trulicity, Mounjaro |
| Glaxosmithkline, LLC. | $219.96 | 2019-2022 | |
| Amarin Pharma, INC. | $176.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $149.82 | 2019-2022 | |
| Amgen INC. | $112.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $108.80 | 2019 | |
| Astellas Pharma US INC | $101.97 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $89.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.92 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.96 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.00 | 2019-2022 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Corium, LLC | $42.38 | 2022 | |
| Eisai INC. | $37.96 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $36.12 | 2019 | |
| Genentech USA, INC. | $35.89 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.75 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $24.42 | 2019 | |
| Inspire Medical Systems, INC. | $23.86 | 2023 | Inspire |
| Orexo US, INC. | $23.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $21.43 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.41 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $18.92 | 2019 | |
| Adlon Therapeutics L.P. | $18.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.20 | 2019 | |
| Bausch Health US, LLC | $12.80 | 2022 | |
| Currax Pharmaceuticals LLC | $12.67 | 2020 | |
| Sanofi Pasteur INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wisser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.